Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeon BiodesignROCO:6499 63 10-Year RORE % is 17.06 as of Mar. 2026. GuruFocus rates ROCO:6499 with a GF Score™ of 63/100 and a GF Value™ of NT$106.93 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 426 Medical Devices & Instruments companies, Medeon Biodesign ranks better than 77.23% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Medeon Biodesign's 10-Year RORE % for the quarter that ended in Mar. 2026 was 17.06%.
The industry rank for Medeon Biodesign's 10-Year RORE % or its related term are showing as below:
ROCO:6499's 10-Year RORE % is ranked better than 77.23% of 426
companies
in the Medical Devices & Instruments industry
Industry Median: 1.12
vs ROCO:6499: 17.06
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Medeon Biodesign 10-Year RORE % Related Terms
Medeon Biodesign 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6499 vs ISRG, BDX, MDLN: 10-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign 10-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Medeon Biodesign (ROCO:6499) has a 10-Year RORE % of 17.06 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Medeon Biodesign and its competitors. According to the industry distribution chart, Medeon Biodesign ranks #97 out of 426 companies in the Medical Devices & Instruments industry, placing it in the top 22.8%.
Is Medeon Biodesign's 10-Year RORE % too high?
Medeon Biodesign's current 10-Year RORE % is 17.06. The Medical Devices & Instruments industry median 10-Year RORE % is 1.12. Medeon Biodesign's value of 17.06 is 1423.2% above this industry median. Based on the distribution chart, Medeon Biodesign ranks #97 out of 426 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medeon Biodesign has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's 10-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #97 out of 426 companies for 10-Year RORE %. This places Medeon Biodesign in the top 23% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 1.12. Medeon Biodesign's value of 17.06 is 1423.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 1.12, based on 426 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current 10-Year RORE % of 17.06 is 1423.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Medeon Biodesign and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 1.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current 10-Year RORE % is 17.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Possible Value Trap. The stock's GF Value™ is NT$106.93, compared to a current price of NT$59.00 — trading 44.8% below its estimated fair value. The current 10-Year RORE % is 17.06 and 1423.2% above the Medical Devices & Instruments industry median of 1.12. Medeon Biodesign's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current 10-Year RORE % is 17.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$59.00 is trading 44.8% below its estimated GF Value™ of NT$106.93.
GuruFocus considers Medeon Biodesign to be Possible Value Trap.
Key valuation signals for ROCO:6499:
10-Year RORE %: 17.06
GF Value™: NT$106.93 vs. price of NT$59.00 (44.8% below fair value)
Industry Position: 1423.2% above the Medical Devices & Instruments median (#97 of 426)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
63GF Score
Get the complete analysis for ROCO:6499
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
